Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1645
This examiner grants 100% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18246467 | STABLE FORMULATIONS OF PROGRAMMED DEATH RECEPTOR 1 (PD-1) ANTIBODIES AND HYALURONIDASE VARIANTS AND FRAGMENTS THEREOF AND METHODS OF USE THEREOF | Non-Final OA | MERCK SHARP & DOHME LLC |
| 18286030 | OFATUMUMAB FOR TREATING MULTIPLE SCLEROSIS IN ASIAN PATIENTS | Non-Final OA | Novartis AG |
| 18247084 | METHODS FOR REDUCING HOST CELL PROTEIN CONTENT IN PROTEIN PURIFICATION PROCESSES | Non-Final OA | Eli Lilly and Company |
| 18557721 | METHODS FOR THE ADMINISTRATION OF ADAMTS BINDING IMMUNOGLOBULINS | Non-Final OA | Sanofi |
| 18259155 | HUMAN CCR8 BINDERS | Non-Final OA | VRIJE UNIVERSITEIT BRUSSEL |
| 18035908 | COMPOSITIONS AND METHODS FOR ENHANCING T CELL PENETRATION OF TUMORS AND CANCERS | Non-Final OA | Georgetown University |
| 18553229 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING GASTROINTESTINAL INFLAMMATION | Non-Final OA | DUPONT NUTRITION BIOSCIENCES APS |
| 18579158 | USE OF LACTOBACILLUS PARACASEI BACTERIAL STRAINS IN THE TREATMENT OF NEWBORNS | Non-Final OA | Alfasigma S.p.A. |
| 18285734 | OFF THE SHELF PROXIMITY BIOTINYLATION ENZYME | Non-Final OA | Stichting Radboud Universiteit |
| 18555103 | A COMBINATION COMPRISING A SPECIFIC HDAC6 INHIBITOR AND AT LEAST ONE CTLA4 CHECKPOINT INHIBITOR | Non-Final OA | ITALFARMACO SPA |
| 18012600 | FORMULATION FOR ANTI-FCRN ANTIBODY | Non-Final OA | HANALL BIOPHARMA CO., LTD. |
| 18321964 | METHODS AND COMPOSITIONS FOR PREVENTING OR DELAYING TYPE 1 DIABETES | Non-Final OA | Provention Bio, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy